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A B S T R A C T
Objectives: Smoking is a common risk factor for chronic obstructive pulmonary disease (COPD) and lung cancer.
Although COPD patients have higher risk of lung cancer compared to non-COPD smokers, the molecular links
between these diseases are not well-defined. This study aims to identify genes that are downregulated by ci-
garette smoke and commonly repressed in COPD and lung cancer.
Materials and methods: Primary human airway epithelial cells (HAEC) were exposed to cigarette-smoke-extract
(CSE) for 10-weeks and significantly suppressed genes were identified by transcriptome array. Epigenetic ab-
normalities of these genes in lung adenocarcinoma (LUAD) from patients with or without COPD were de-
termined using genome-wide and gene-specific assays and by in vitro treatment of cell lines with trichostatin-A
or 5-aza-2-deoxycytidine.
Results: The ten most commonly downregulated genes following chronic CSE exposure of HAEC and show
promoter hypermethylation in LUAD were selected. Among these, expression of CCNA1, SNCA, and ZNF549 was
significantly reduced in lung tissues from COPD compared with non-COPD cases while expression of CCNA1 and
SNCA was further downregulated in tumors with COPD. The promoter regions of all three genes were hy-
permethylated in LUAD but not normal or COPD lungs. The reduced expression and aberrant promoter hy-
permethylation of these genes in LUAD were independently validated using data from the Cancer Genome Atlas
project. Importantly, SNCA and ZNF549 methylation detected in sputum DNA from LUAD (52% and 38%) cases
were more prevalent compared to cancer-free smokers (26% and 15%), respectively (p < 0.02).
Conclusions: Our data show that suppression of CCNA1, SNCA, and ZNF549 in lung cancer and COPD occurs with
or without promoter hypermethylation, respectively. Detecting methylation of these and previously identified
genes in sputum of cancer-free smokers may serve as non-invasive biomarkers for early detection of lung cancer
among high risk smokers including COPD patients.
1. Introduction
Cigarette-smoke (CS) exposure plays a major role in the develop-
ment of chronic obstructive pulmonary disease (COPD) and lung cancer
[1]. Several independent studies have shown that smokers with COPD
have a 2–4-fold higher risk of developing lung cancer compared with
smokers without COPD [2,3]. Evaluation of the National Lung
Screening Trial (NLST) data for patients with spirometry information
[4], a meta-analysis of eighteen published prospective cohort studies
involving 12,442 lung cancer cases [5], and another meta-analysis
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North Carolina School of Medicine were used for air-liquid-interface
cultures. All samples were obtained with written informed consent from
patients, and the study was approved by each institute’s Ethics Com-
mittee. In addition, five human bronchial epithelial cell lines (HBEC)
immortalized as described [27], and 20 NSCLC cell lines (Table S3),
whose sources, authentications, and handling methods are described in
the online supplement were also studied.
2.2. Air-liquid-interface (ALI) culture and cigarette-smoke exposure
Primary HAEC isolated from never-smokers (n = 11) were driven to
differentiation using ALI culture as described [28]. A pair of HAEC
cultures from each individual were treated twice-a-week for 10 weeks
either with vehicle (culture medium) or medium containing 40 μg/mL
cigarette-smoke-extract (CSE). The CSE was prepared using Cigarette
smoke (CS) generated from Kentucky Reference cigarettes (Type: 3R4F,
Center for Tobacco Reference Products, Kentucky Tobacco Research &
Development Center, Lexington, KY). Briefly, a modified AMESA Mark
III smoke machine (AMESA Technologies, Switzerland) was used to
generate the CS in a 1-m3 chamber using Health Canada Intense puffing
regime (puff volume: 55 cc, puff duration 2 s, frequency 30 s, blocked
ventilation holes). The CS was collected by pulling it through pre-
weighed glass fiber filters (Type GF/A, GE Whatman), the CS mass was
determined from the final weight of the filters at the end of sampling,
and the filters were stored at −80 °C until use. The filters were in-
cubated for 1 h at 37 °C with 5% CO2 in serum-free medium to generate
a 100 μg/mL stock solution, fresh CSE solution prepared prior to each
treatment, filter-sterilized, and diluted to a final concentration of 40 μg/
mL in the culture medium.
2.3. Trichostatin-A or 5-aza-2-deoxycytidine treatments and gene
expression analysis
The impact of DNA methylation or histone modification on gene
expression were assessed as described [29–31]. Briefly, HAEC and
NSCLC cell lines were treated with 500 nM DNA methyltransferases
inhibitor 5-aza-2-deoxycytidine (DAC) every 12 h for 96 h or 300 nM
histone deacetylase inhibitor Trichostatin-A (TSA) for 18 h prior to
harvest in Trizol. For transcriptome analysis, total RNA was isolated,
amplified, and biotin labeled using the Illumina TotalPrep RNA Am-
plification Kit, and 1 μg biotin-labeled cRNA was hybridized, and
probes were visualized using Illumina’s iScan and GenomeStudio soft-
wares. All arrays passed quality checks including visual inspection for
artifacts and the distribution of signal and background intensity for red
and green channels. For gene-specific quantitative PCR, RNA isolated
from the various in vitro treatments (CSE, TSA, or DAC) or patient
samples was reverse transcribed, expression of target genes quantified
as described [29,31,32], and the relative gene expression levels were
calculated using ΔΔCT method [33]. RNA-seq data for large number of
lung adenocarcinoma (LUAD, n = 517) and normal lung (n = 110)
tissue samples was obtained from the Cancer Genome Atlas (TCGA)
project https://tcga-data.nci.nih.gov/tcga/ and used for validation of
our findings.
2.4. DNA extraction and methylation analysis
DNA extraction, bisulfite modification, and methylation analysis
using Combined Bisulfite Modification and Restriction Analysis
(CoBRA), Methylation-Specific PCR (MSP), and for sputum samples,
nested MSP assays, were conducted as described [19,30,34]. The
primer sequences and amplification conditions are shown in Table S4.
Genome-wide methylation of lung tumor-normal pairs was quantified
using the Infinium HumanMethylation450 BeadChip (HM450K) exactly
as described [35]. Briefly, 500 ng bisulfite-modified DNA was whole-
genome amplified, enzymatically fragmented, precipitated, re-sus-
pended in hybridization buffer, and hybridized onto the
involving 31 case-control and 8 cohort studies found that the relative 
risk for lung cancer is higher for patients with COPD than those without 
[6]. These findings suggest that smoking-induced molecular alterations 
in lung cancer may already be present in patients with COPD and may 
contribute to the increased risk of lung cancer among COPD cases [7].
Epigenetic modifications l ink the impact of environmental factors 
such as smoking with inherent or acquired genetic predisposition to 
various lung diseases and increase susceptibility [8]. Aberrant DNA 
methylation of CpG islands across the promoter regions of tumor-sup-
pressor genes is one of the most common epigenetic change caused by 
smoking [9–13]. Our previous epigenome-wide association study 
compared the epigenetic changes found in lung tumors and cancer-free 
lung tissue pairs from non–small-cell lung cancer (NSCLC) cases with or 
without COPD [14]. We found that expression of some genes, such as 
CCDC37 and MAP1B, is downregulated in the lungs of COPD subjects, 
further reduced in lung tumors, and even more suppressed in tumors 
from COPD cases. The suppression of these genes was enhanced in lung 
tumors by promoter hypermethylation that establishes a long-term loss 
of promoter activity [15,16]. We have also shown that high methyla-
tion index (methylation of ≥3 genes in a 12 gene-panel) in sputum 
predicts decline in forced expiratory volume in 1 s (FEV1), lung cancer 
incidence, and all-cause mortality in smokers [17].
Based on these findings w e h ypothesized t hat C S e xposure sup-
presses expression of specific genes in airway epithelial cells, and these 
changes become more evident in lung cancer due to clonal expansion of 
the transformed cells. We and others have previously demonstrated that 
the promoter regions of genes with aberrantly repressed expression are 
prone to methylation during transformation [16,18]. The addition of 
promoter methylation not only reinforces the downregulation of such 
genes and stabilizes long term repression, but also provides potential 
DNA biomarkers that aid early detection in noninvasive samples such as 
sputum from high risk smokers. This study compared genome-wide 
downregulation of genes in primary human airway epithelial cells fol-
lowing chronic CS-extract (CSE) exposure and promoter CpG island 
methylation in COPD and lung cancer to identify genes commonly 
suppressed in the two major lung diseases. Importantly, the identified 
epigenetic changes were more frequently detected in the sputum of 
lung cancer cases compared to cancer-free smokers, suggesting that 
they may be used as part of a biomarker panel. The use of these and our 
previously validated non-invasive sputum biomarkers [17,19–21] to-
gether with low dose computed tomography (LDCT) could improve the 
specificity of early detection and treatment strategies for lung cancer.
2. Materials and methods
2.1. Study subjects and samples
Frozen lung adenocarcinoma (LUAD) samples from 90 patients (47 
with and 43 without COPD) were obtained from tumor banks at the 
University of New Mexico (UNM) and the Mayo Clinic. Characteristics 
of these patients are shown in Table S1. All tumors have ≥75% tumor 
purity, and cancer-free lung tissues collected from sites most distant to 
the tumor in the resected lobe were available for a subset of these cases. 
COPD status and severity was defined according to the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) classification [22]. 
Sputum samples from the Lovelace Smokers cohort (n = 108) and New 
Mexico Lung Cancer cohort (n = 29), whose participants are from the 
Albuquerque, NM metropolitan area since 2001 [23–26] were used for 
methylation analysis. Characteristics of these subjects are described 
under Table S2. Normal human bronchial epithelial cells (NHBEC) 
collected from 5 cancer-free smokers at UNM through diagnostic 
bronchoscopy [10] and peripheral blood mononuclear cells (PBMC) 
obtained from 5 healthy donors were used as normal control. Primary 
human airway epithelial cells (HAEC) isolated from the lungs of 11 
cancer-free never-smokers that were not suited for transplantation 
under the protocol and consent form approved by the University of
ZNF549, showed tumor-specific aberrant hypermethylation in multiple
NSCLC cell lines and lung tumors but not in any of the distant normal
lung tissue (DNLT) samples (Table 1).
3.2. Suppression of CS-regulated genes in COPD and lung cancer
We confirmed the suppression of CCNA1, SNCA, and ZNF549 by
chronic CSE exposure of differentiated HAEC using q-PCR (Fig. S1B).
Whether the suppression was potentially due to histone modifications
was indirectly investigated by treating the CS-treated HAEC with the
histone deacetylase inhibitor, Trichostatin-A (TSA). SNCA and ZNF549
expression levels already responded to TSA alone and the suppression
by chronic CS was partially restored (Fig. S1B). Whether these genes are
progressively suppressed during the development of COPD and lung
Fig. 1. A multifaceted strategy was used to uncover cigarette-smoke regulated
genes linking COPD to lung cancer.
Table 1
Genes suppressed by cigarette smoke (CS) exposure and methylated in lung
cancer.
Genes Down in CS
exposed HAECs
(n = 11)








CCNA1a 9 (82%) 4 (20%) 10 (29%)c 0 (0%)
CPA6 8 (73%) 1 (5%) 25 (71%) 2 (33)
CRISPLD1 9 (82%) 3 (15%) 31 (89%) 5 (83)
CYYR1 7 (64%) 12 (60%) 34 (98%) 6 (100)
EFEMP1 9 (82%) 4 (20%) 35 (100%) 6 (100)
FSD1 7 (64%) 5 (25%) 34 (97%) 6 (100)
SCARA3 6 (55%) 2 (10%) 1 (3%) 0 (0%)
SERPINE2 11 (100%) 1 (5%) 0 (0%) 0 (0%)
SNCAa 11 (100%) 9 (45%) 20 (57%)c 0 (0%)
ZNF549a 6 (55%) 4 (20%) 11 (31%)c 0 (0%)
a Genes that are commonly repressed by CS and methylated in NSCLC cell
lines and tumors but not in the distant normal lung tissues (DNLT) were se-
lected for detailed analysis.
b The 35 lung adenocarcinoma samples were obtained from 18 COPD and 17
non-COPD cases.
c CCNA1, SNCA, and ZNF549 promoters showed tumor-specific methylation.
All 3 genes were methylated in 4/35 (11%) of the samples, whereas at least 2 or
1 of the three genes were methylated in 14/35 (40%) and 23/35 (66%) of the
adenocarcinoma samples, respectively.
HumanMethylation450 Bead-Chips according to the standard Infinium 
protocol. The beadchips were then processed through primer extension, 
immunohistochemistry staining, coated, and imaged on an Illumina 
iScan. Quantitative methylation data for large number of LUAD 
(n = 450) and normal lung (n = 74) tissue samples, which like our 
study generated by TCGA using HM450K, was used for validation of our 
findings.
2.5. Statistical analysis
Gene methylation and patient characteristics including age, sex, 
smoking, and COPD status were summarized with mean and standard 
deviation for continuous variables and proportions for categorical 
variables. For RNA expression, the statistical platform R and packages 
from Bioconductor were used for all computation [36,37]. The log ratio 
of red signal to green signal was calculated after background subtrac-
tion and LoEss normalization as implemented in the limma package 
from Bioconductor [37]. The HM450K data for 485,577 probes across 
the epigenome of samples evaluated was calculated using GenomeS-
tudio® Methylation module software as methylation beta-value 
(β=intensity of the Methylated allele (M)/(intensity of the Un-
methylated allele (U)+intensity of the Methylated allele (M)+100) as 
described [35]. HM450K data for lung tissue and tumor samples from 
COPD and non-COPD cases was compared using β-regression analysis 
[38]. The association between methylation and COPD or lung cancer 
was assessed using logistic regression. Area under the curve (AUC) of a 
receiver operating characteristic (ROC) curve was calculated to assess 
the prediction performance of logistic regressions for smoking pack 
years and gene methylation. The methylation status of statistically 
significant g enes a s i ndependent v ariables w as i ncluded i n t he basic 
model to evaluate the delta change in AUC. Gene expression levels were 
compared using two-tailed T-test for unequal variance (COPD vs. non-
COPD cases) and pairwise T-test (tumor vs. normal pairs). Pathway 
analysis of CSE exposure regulated genes was performed using the In-
genuity® Pathway Analysis (IPA®) program from Qiagen. All analyses 
were conducted in SAS 9.4 and R 3.4
3. Results
3.1. Discovery of cigarette-smoke-regulated genes linked to COPD and lung 
cancer
The general strategy to identify genes that are suppressed by chronic 
CS exposure of airway epithelia and may contribute to COPD and lung 
cancer is depicted in Fig. 1. Primary HAEC derived from 11 never-
smokers were differentiated in Air-liquid-interface (ALI) cultures and 
treated with vehicle or 40 μg/mL CSE twice-a-week for 10 weeks. 
Genome-wide transcriptome analysis identified s ignificant down-
regulation of 632 genes in the CSE exposed cells (p < 0.05, paired t-
test). Pathway analysis of these genes revealed that protein kinase A, 
p53, and interferon signaling pathways are among the top canonical 
signaling pathways while cellular movement, organization, main-
tenance, morphology, and cell-to-cell signaling were the top cellular 
functions affected (Fig. S1A). The genes that are hypermethylated in 
lung cancer were identified u sing g enome-wide D NA methylation 
analysis (HM450K) of 20 NSCLC cell lines. About half of the 632 CSE-
downregulated genes have a CpG island in their promoter regions and 
10 of these, which were significantly downregulated in the majority of 
HAEC samples (≥6/11) and showed promoter hypermethylation in 
NSCLC cell lines were selected (Table 1). To identify the genes that are 
reduced in primary lung tumors with possible distinction between cases 
with or without COPD, we used a list of methylated genes we had 
previously identified f rom 3 5 l ung a denocarcinoma ( LUAD) patients 
with (n = 18) or without COPD (n = 17) [14]. Characteristics of pa-
tients whose lung or sputum samples were used in this study are shown 
under Tables S1 and S2, respectively. Three genes, CCNA1, SNCA, and
carcinogenesis was investigated using mRNA from normal lung tissues
(NLT) obtained from never-smokers (NLT-NS, n = 5) and smokers
(NLT-S, n = 21), tumors with distant normal lung tissue (DNLT) pairs
from LUAD patients (n = 37), and NSCLC cell lines (n = 20). Since the
tumors and DNLT pairs were obtained from smokers with (n = 20) or
without (n = 17) COPD, they were subdivided into four groups. DNLT
with (DNLT + COPD, n = 20) and without COPD (DNLT-COPD,
n = 17), and tumors with (Tumor + COPD, n = 20) and without COPD
(Tumor-COPD, n = 17). Expression of CCNA1, SNCA, and ZNF549 in
normal lung tissue from smokers (NLT-S and DNLT-COPD) was not
significantly different from the expression in never-smokers (NLT-NS,
Fig. 2A–C). However, expression of the three genes was significantly
suppressed in DNLT + COPD compared to the normal lung tissues
(NLT-NS, NLT-S) and/or DNLT-COPD. CCNA1 and SNCA mRNA levels
were also significantly reduced in Tumor-COPD and further reduced in
Tumor + COPD (Fig. 2A, B). In contrast, the reduced ZNF549 mRNA
levels were mainly associated with COPD (DNLT + COPD and
Tumor + COPD) and Tumor-COPD did not show significant suppres-
sion (Fig. 2C). All three genes were significantly reduced in NSCLC cell
lines compared to normal lung (LUAD-COPD). Analysis of RNA-seq data
from the Cancer Genome Atlas (TCGA) database independently vali-
dated the significant repression (p < 0.0001) of CCNA1 and SNCA in
LUAD tumors (n = 517) compared to normal lung tissue (n = 110,
Fig. 2D). Our data showed that ZNF549 expression in lung tumors
without COPD (Tumor-COPD, Fig. 2C) was not significantly reduced
and this was also supported by the similar expression of the gene in
normal vs. LUAD samples from TCGA, where the COPD status of cases
are unknown.
3.3. Tumor-specific methylation of CS-regulated genes in lung cancer
The methylation status of CCNA1, SNCA, and ZNF549 promoter CpG
islands were determined using quantitative and qualitative assays. The
HumanMethylation450 BeadChip (HM450K) quantifies the methylation
levels of 9, 10, and 7 probes across the promoter CpG islands of CCNA1,
SNCA, and ZNF549, respectively (Fig. S2A–C). The lowest level of
methylation for all three genes was detected in normal bronchial epi-
thelial cells (NHBEC7) and distant normal lung tissue (DNLT), while the
highest methylation levels were found in the NSCLC cell lines Calu6 (for
CCNA1 and ZNF549)and SKLU1 (for SNCA, Fig. S2A–C). The methyla-
tion levels of all three genes were significantly higher in the tumors
than the DNLT. Similarly, the DNLT-COPD and DNLT + COPD samples,
regardless of the COPD status, showed the lowest methylation levels for
all three genes compared to lung tumors with or without COPD
(Fig. 3A–C). Overall, tumors from COPD patients (LUAD + COPD)
showed the highest methylation among primary tissues. The aberrant
promoter CpG island hypermethylation of all three genes in lung cancer
regardless of COPD status was independently validated using TCGA
data for 450 LUAD cases (Fig. 4A-3). Details of the methylation data for
the TCGA samples are shown in Tables S5–S7.
The tumor-specific methylation of these genes, which is often ne-
cessary for simple biomarker screening of large patient samples, was
further verified using two independent methylation assays, the semi-
quantitative Combined Bisulfite Modification and Restriction Analysis
(CoBRA, Fig. S3A–C), and the highly sensitive, qualitative Methylation-
Specific PCR (MSP, Table S8) assays. These assays confirmed that all
three promoter CpG islands were unmethylated in normal samples in-
cluding differentiated HAEC cultures with or without CSE exposure
(Fig. S3A–C top panels), normal bronchial epithelial cells, and periph-
eral blood mononuclear cells (Fig. S3A–C middle panels). In contrast,
all three promoter CpG islands were hypermethylated in a subset of
NSCLC cell lines including complete methylation in some cell lines
(shown by the complete digestion in the presence of the BstU1 re-
striction enzyme, Fig. S3A–C bottom panels). Evaluation of these genes
using the highly sensitive MSP assay showed that the CCNA1, SNCA,
and ZNF549 promoters were methylated in 60, 65, and 25% of NSCLC
cell lines (n = 20) and 56, 87, and 40% of LUAD tumors (n = 55), re-
spectively, (Table S8).
3.4. Epigenetic changes suppress transcription of these genes
CCNA1 expression is completely silenced in NSCLC cell lines with
hypermethylated promoter CpG island (e.g. Calu6, Calu3) but
Fig. 2. Gene expression changes in COPD and lung cancer. The expression le-
vels of (A)CCNA1, (B)SNCA, and (C)ZNF549 in normal lung tissues (NLT) ob-
tained from cancer-free never smokers (NLT-NS) and smokers (NLT-S), tumor-
normal pairs from lung cancer patients, and NSCLC cell lines were quantified
using gene-specific expression assays. The distant normal lung tissue (DNLT)
and tumor pairs were all from smoker LUAD cases with or without COPD. Thus,
they were separated into the following 4-groups: DNLT without COPD (DNLT-
COPD) or with COPD (DNLT + COPD) and tumors without COPD (Tumor-
COPD) or with COPD (Tumor + COPD). Expression is measured relative to the
level in NLT-NS and the significant changes from NLT-NS ( ), NLT-S (♦), DNLT-
COPD (Δ), DNLT + COPD (⬜), or Tumor-COPD (◼) are shown. D) RNA-seq
data for the expression of CCNA1, SNCA, and ZNF549 in normal lung tissues
and LUAD samples from TCGA database was used to independently validate the
repression of these genes.
expressed similar to DNLT in those without promoter methylation e.g.
SKLU1 (Fig. S2A, S3A, and S4A). Similarly, complete or significant si-
lencing of SNCA and ZNF549 were seen in cell lines where the promoter
CpG islands of these genes were hypermethylated (Fig. S2B, C, S3B, C,
and S4B, C). The reversibility of epigenetic silencing of these genes in
lung cancer was investigated using in vitro treatment of these cell lines
with the histone deacetylase inhibitor Trichostatin-A (TSA) or the DNA
methyltransferases inhibitor 5-aza-2-deoxycytidine (DAC) as described
[30]. Compared to vehicle (culture media), treatment of NSCLC cells
with DAC partially or completely restored expression of CCNA1, SNCA,
and ZNF549 (Fig. S4A–C). In contrast, TSA treatment increased ex-
pression only in the cell lines with partial or no methylation such as
SNCA and ZNF549 in H358 (Fig. S4B-C) or ZNF549 in H1838 (Fig. S4C).
These results indicate that DNA methylation rather than histone dea-
cetylation is primarily responsible for the transcriptional silencing or
repression of these genes in lung cancer.
3.5. Methylation of CCNA1, SNCA, and ZNF549 in sputum samples
Aberrant promoter methylation of lung cancer-related genes in
sputum samples from high risk smokers can be detected up to two years
prior to lung cancer diagnosis [19,20]. Therefore, the potential use of
CCNA1, SNCA, and ZNF549 promoter methylation as non-invasive
biomarkers in sputum samples from smokers with or without COPD
and/or LUAD was evaluated. The prevalence for methylation of all
three genes in the sputum samples from cancer-free smokers with COPD
(n = 32) was similar to smokers without COPD (n = 76, Table 2). In a
separate set of analyses, the methylation of each gene in sputum sam-
ples from cancer-free smokers (with or without COPD, n = 108) were
compared with sputum samples from smokers with LUAD (n = 29).
CCNA1 methylation was not detected in any of the sputum samples
from LUAD cases. In contrast, methylation of SNCA and ZNF549 was
increased from 26% and 15% in the sputum of cancer-free smokers
(lung cancer controls) to 52% and 38% in sputum from LUAD cases
(Odds ratio = 3.06 and 3.44), respectively (Table 2). The AUC classi-
fication accuracy for lung cancer was 59% for pack years, 70% for
Fig. 3. Differentially methylated regions across
the promoter regions of (A) CCNA1, (B) SNCA,
and (C) ZNF549 in lung cancer. The human
methylation450beadchip (HM450K) was used
to quantify the methylation levels across the
promoter CpG islands of the three genes in lung
tumor and distant normal lung tissue pairs
from smoker LUAD cases with or without
COPD. The y-axis shows the level of methyla-
tion in β–values ranging 0 to 1 (1 indicating
complete or 100% methylation). The x-axis
labels indicate the shortened HM450K probe ID
numbers of targeted CpGs. The full probe ID
numbers along with detailed methylation data
for TCGA samples are shown in supplementary
Tables S3–S5.
SNCA and 68% for ZNF549, and improved to 72% when all three
variables were included in the model (Supplemental Table S9).
4. Discussion
This study combined genome-wide gene expression and DNA
methylation analyses to identify genes that are downregulated by ci-
garette-smoke and may contribute to COPD and lung cancer develop-
ment. The suppression of CCNA1, SNCA, and ZNF549 expression fol-
lowing chronic CSE-exposure and in the lungs of COPD patients was
potentially mediated by histone modifications without abnormal me-
thylation of their promoter CpG islands. However, extensive promoter
Fig. 4. Independent validation of tumor-specific promoter hypermethylation of (A) CCNA1, (B) SNCA, and (C) ZNF549 in lung cancer. Quantitative methylation
(HM450K) data for the CpG islands across the promoter regions of the three genes in normal lung and LUAD samples were obtained from the publicly available TCGA
(the Cancer Genome Atlas) database. The tumor specific hypermethylation shown across the promoter CpG islands of the three genes independently validated our
findings. The details of the figures are similar to Fig. 3 above.
Table 2
Prevalence for methylation of genes in sputum samples from cancer-free smokers (CFS) with or without COPD and smokers with lung adenocarcinoma (LUAD).
Genes Methylated OR (95% CI)b
(CFS vs. LUAD)








CCNA1 5/76 (7%) 3/32 (9%) 8/108 (7%) 0/29 (0%) ND
SNCA 21/76 (28%) 7/32 (22%) 28/108 (26%) 15/29 (52%) 3.06 (1.3–7.1)
ZNF549a 9/75 (12%) 7/31 (23%) 16/106 (15%) 11/29 (38%) 3.44 (1.4–8.6)
*Statistically significant differences are shown in bold.
a ZNF549 assay failed for 2 samples, one non-COPD and one COPD.
b The differences in the methylation of each of the three genes is compared between total CFS (COPD and non-COPD samples combined) versus LUAD. ND (not
determined).
respectively. It also regulates various cellular functions by binding to
key cell cycle regulators such as E2F-1, Rb, and p21 proteins [44,45].
CCNA1 knockdown in lung cancer cells increases cancer properties such
as epithelial-to-mesenchymal transition (EMT), cell migration, and in-
vasion [46] suggesting that its repression in COPD may similarly con-
tribute to lung cancer development. In agreement with this premise, the
detection of CCNA1 methylation and its prognostic values have been
previously reported in various malignancies including lung cancer
[47–49]. SNCA encodes for α-synuclein that is abundantly expressed in
the brain and helps to integrate presynaptic signaling and membrane
trafficking. Thus, SNCA abnormalities including its promoter methyla-
tion are primarily associated with neurological disorders such as Par-
kinson and Alzheimer's diseases [50–52]. The down-regulation of SNCA
expression in LUAD is also correlated with shorter survival time of
patients [53]. Our findings confirm SNCA downregulation in LUAD and
also revealed its repression in cancer-free COPD lung. ZNF549 encodes
for a zinc-finger protein that is ubiquitously expressed including in the
lungs. Yet, it is also one of the genes that show significantly higher
methylation in nasopharyngeal carcinoma [54], suggesting aberrant
methylation of its gene promoter occurs in various tumors. However,
the normal function of ZNF549 and its potential role in COPD or lung
cancer are unclear.
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hypermethylation that is associated with transcriptional repression of 
these genes was found specifically in the tumors but not normal lung 
tissue samples from LUAD cases. The aberrant methylation of these 
genes was also detected in sputum samples from high risk smokers, 
suggesting that these changes may have originated from early (pre) 
malignant cells and could serve as novel biomarkers for early detection 
of lung cancer among heavy smokers. The reduced expression of these 
genes in CSE-exposed primary HAEC and further suppression in lung 
tissue from COPD patients and in lung tumors show that epigenetic 
repression of these genes is a common abnormality in COPD and lung 
cancer. Taken together, these findings w ill s upport f uture s tudies to 
establish a potential mechanistic link between the two major smoking-
induced lung diseases.
Epigenetic modifications a re k ey m echanisms t hat a llow c ells to 
regulate gene expression networks in response to environmental stimuli 
[39]. Cigarette-smoke exposure modulates expression of many genes 
and induces genetic and epigenetic lesions across the genome [40]. Our 
group has identified expression changes of many genes in airway epi-
thelial cells following exposure to cigarette-smoke or CSE [41,42]. We 
have previously demonstrated that in vitro exposure of bronchial epi-
thelial cells to tobacco carcinogens initially suppresses expression of 
genes and microRNAs through histone modifications (e.g. acetylation, 
methylation) [13,18]. These early changes create a condensed chro-
matin structure that leads to a reversible and transient transcriptional 
repression. In addition, the transient downregulation or silencing of 
these genes and the associated reduction in promoter activity make 
their promoter CpG islands prone to aberrant methylation, which then 
leads to the establishment of a long-term repressive state. These early 
changes become more evident during malignant transformation and 
clonal expansion make these abnormalities easily detectable, and po-
tential biomarkers for early detection of lung cancer. Our findings that 
show initial suppression of CCN A1, SN CA, and ZN F549 following 
chronic CSE exposure with no apparent changes in promoter methyla-
tion and the detection of hypermethylation in the tumor samples sup-
port this pattern. The role of cigarette-smoke exposure in creating DNA 
adducts and impacting DNA repair pathways within lung epithelia and 
how these genetic lesions contribute to transcriptional repression and 
epigenetic changes in chronic respiratory diseases such as COPD and 
lung cancer have also been previously demonstrated [21,43].
Early detection is the most critical step for improving cancer sur-
vival. Unfortunately, unlike for breast and colorectal cancers, highly 
effective a nd s pecific sc reening me thod fo r lu ng ca ncer is  no t yet 
available. As a result, many lung cancer patients are diagnosed (often 
with advanced disease) following x-rays or scans for unrelated reasons, 
and lung cancer remains the leading cause of cancer-related mortality 
worldwide. Since 2015, the Centers for Medicare & Medicaid Services 
(CMS) approved the use of low dose computed tomography (LDCT) for 
lung cancer screening if certain eligibility requirements are met. 
However, the promise of LDCT in improving survival comes with an 
increased treatment-related risk and cost due to high false-positive rates 
[37]. Thus, the use of non-invasive methods to supplement lung cancer 
screening approaches for high risk individuals including COPD patents 
is urgently needed. The discovery of novel sputum biomarkers in this 
and previous studies will contribute towards achieving this goal. The 
role of CCNA1, SNCA, and ZN F549 in linking COPD to lung cancer 
needs independent validation. Although we used TCGA data to validate 
these genes as lung cancer biomarkers, their suppression in COPD could 
not be independently verified due to absence of pulmonary function test 
data for an adequate number of TCGA samples.
The concurrent suppression of CCN A1 and SN CA with the devel-
opment of lung adenocarcinoma supports the hypothesis that these 
genes may have a tumor-suppressor role in lung cancer. CCNA1 is a 
member of the cyclin family whose protein levels dramatically fluctuate 
during cell cycle and function as regulators of cyclin-dependent kinases 
(CDKs). CCN A1 binds to CDK2 and CDC2 kinases to modulate two 
distinct kinase activities in the S and G2-M phases of the cell cycle,
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